Lee Frank D. 4

What Happened

• Frank D. Lee, CEO of Pacira BioSciences (PCRX), was granted 261,818 restricted stock units (RSUs) on Feb 11, 2026. The Form 4 records the acquisition price as $0.00 per unit (typical for compensation awards); the filing classifies the transaction as an Award/Grant (code A).
• These RSUs do not convert into shares immediately; they represent the contingent right to receive one share of common stock per unit upon vesting.

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13.
• Grant size: 261,818 RSUs; reported acquisition price: $0.00 per RSU.
• Vesting: Four equal annual installments beginning Feb 15, 2027, contingent on continuous service (per footnote).
• Shares owned after transaction: Not disclosed in the Form 4.
• Filing timeliness: Filed two days after the grant (within the normal 2-business-day reporting window).

Context

• This is a compensation award, not a purchase or sale; RSUs typically vest over time and convert to common stock only if vesting conditions are met. Such grants are routine for executive compensation and do not by themselves indicate a buy/sell decision by the insider.